Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation

Next Previous
Trial Profile

A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fludarabine (Primary) ; Melphalan (Primary) ; Methotrexate; Mycophenolate mofetil; Mycophenolate mofetil; Tacrolimus; Tacrolimus
  • Indications Acute myeloid leukaemia; Aplastic anaemia; Bone marrow disorders; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Diffuse large B cell lymphoma; Graft-versus-host disease; Haematological malignancies; Hodgkin's disease; Immunological disorders; Lymphoid leukaemia; Lymphoproliferative disorders; Multiple myeloma; Myelodysplastic syndromes; Myelofibrosis; Myeloproliferative disorders; Non-Hodgkin's lymphoma; Paroxysmal nocturnal haemoglobinuria; Precursor cell lymphoblastic leukaemia-lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Biomarker; Therapeutic Use

Most Recent Events

  • 16 Sep 2019 Status changed from active, no longer recruiting to completed.
  • 15 Mar 2019 Planned End Date changed from 1 Mar 2019 to 1 Aug 2019.
  • 15 Jan 2019 Planned End Date changed from 1 Dec 2018 to 1 Mar 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top